SCHEMBL26686635

SCHEMBL26686635

Clc1ccnc2[nH]c(CCN3CCOCC3)cc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCNK O75909 2/20 0.48
▸ CDK12 Q9NYV4 2/20 0.48
▸ DRD2 P14416 1/20 0.47
▸ DRD4 P21917 1/20 0.47
▸ DRD3 P35462 1/20 0.47
▸ SIGMAR1 Q99720 1/20 0.47
▸ CDK9 P50750 3/20 0.43
▸ CDC7 O00311 1/20 0.43
▸ PIM1 P11309 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ CLK4 Q9HAZ1 1/20 0.40
▸ CCNT1 O60563 2/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ EIF2AK2 P19525 1/20 0.40
▸ METAP2 P50579 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26686338 0.93 CCNK (0.47) CCNKCDK12DRD2DRD4DRD3
SCHEMBL26686575 0.87 CCNK (0.58) CCNKCDK12CDK9CDC7PIM1
SCHEMBL26889405 0.87 DRD2 (0.46) CCNKCDK12DRD2DRD4DRD3
SCHEMBL26889438 0.80 HRH3 (0.44) DRD2DRD4DRD3CDK9CDC7
SCHEMBL26686734 0.78 CCNK (0.44) CCNKCDK12DRD2DRD4DRD3
SCHEMBL31240772 0.75 CSF1R (0.67) CDK9CDC7PIM1
SCHEMBL26889338 0.74 CCNK (0.58) CCNKCDK12DRD2DRD4DRD3
SCHEMBL26686463 0.74 CDK9 (0.42) CCNKCDK12CDK9CDC7PIM1
SCHEMBL26889371 0.74 CCNK (0.45) CCNKCDK12DRD2DRD4DRD3
SCHEMBL26889301 0.74 CCNK (0.45) CCNKCDK12DRD2DRD4DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304576-A1 IKK INHIBITORS CANCER RESEARCH TECH LTD (GB) 2025-10-02 — — US disclosed
EP-4522597-A1 IKK INHIBITORS Cancer Research Technology Limited (GB) 2025-03-19 — — EP disclosed
CN-119562945-A IKK inhibitors 癌症研究技术有限公司 2025-03-04 — — CN disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304576-A1 IKK INHIBITORS NFKBIA, IKBKE, IKBKB CCNK 222/4885CDK12 171/4885DRD2 4529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback